Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?

Nadine Kronfli, Jim Young, Shouao Wang, Joseph Cox, Sharon Walmsley, Mark Hull, Curtis Cooper, Valérie Martel‐Laferrière, Alexander Wong, Neora Pick, Marina B. Klein, Lisa Barrett, Jeff Cohen, Brian Conway, Pierre Côté, M. John Gill, Shariq Haider, Joan Montaner, Erica E. M. Moodie, Anita Rachlis, Danielle Rouleau, Roger Sandre, Mark Tyndall, Stephen Sanche, Marie-Louise Vachon, David WongClinical 2020 · DOI · OpenAlex

Abstract

Abstract Background Noninvasive markers of liver fibrosis such as aspartate aminotransferase-to-platelet ratio (APRI) and transient elastography (TE) have largely replaced liver biopsy for staging hepatitis C virus (HCV). As there is little longitudinal data, we compared changes in these markers before and after sustained virologic response (SVR) in human immunodeficiency virus (HIV)-HCV coinfected patients. Methods Participants from the Canadian Coinfection Cohort study who achieved SVR after a first treatment with either interferon/ribavirin or direct acting antivirals (DAAs), with at least 1 pre- and posttreatment fibrosis measure were selected. Changes in APRI or TE (DAA era only) were modeled using a generalized additive mixed model, assuming a gamma distribution and adjusting for sex, age at HCV acquisition, duration of HCV infection, and time-dependent body mass index, binge drinking, and detectable HIV RNA. Results Of 1981 patients, 151 achieved SVR with interferon and 553 with DAAs; 94 and 382 met inclusion criteria, respectively. In the DAA era, APRI increased (0.03 units/year; 95% credible interval (CrI): −.05, .12) before, declined dramatically during, and then changed minimally (−0.03 units/year; 95% CrI: −.06, .01) after treatment. TE values, however, increased (0.74 kPa/year; 95% CrI: .36, 1.14) before treatment, changed little by the end of treatment, and then declined (−0.55 kPa/year; 95% CrI: −.80, −.31) after SVR. Conclusions TE should be the preferred noninvasive tool for monitoring fibrosis regression following cure. Future studies should assess the risk of liver-related outcomes such as hepatocellular carcinoma according to trajectories of fibrosis regression measured using TE to determine if and when it will become safe to discontinue screening.
BibTeX
@inproceedings{kronfli2020liver,
  author = {Nadine Kronfli and Jim Young and Shouao Wang and Joseph Cox and Sharon Walmsley and Mark Hull and Curtis Cooper and Valérie Martel‐Laferrière and Alexander Wong and Neora Pick and Marina B. Klein and Lisa Barrett and Jeff Cohen and Brian Conway and Curtis Cooper and Pierre Côté and Joseph Cox and M. John Gill and Shariq Haider and Mark Hull and Marina B. Klein and Joan Montaner and Erica E. M. Moodie and Neora Pick and Anita Rachlis and Danielle Rouleau and Roger Sandre and Mark Tyndall and Stephen Sanche and Marie-Louise Vachon and Sharon Walmsley and Alex Wong and David Wong and David Wong},
  title = {{Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?}},
  booktitle = {Clinical},
  year = {2020},
  doi = {10.1093/cid/ciaa702},
}

Loading related content...

Figure